|
Market Cap (17-May) $1,668,273,536 (454th) |
Close (30-Jun) $12.25 |
Volume (30-Jun) 261,029 |
Shortsold (5-May) 7,255,072 (5.76%) (39th) |
|
52w High $24.00 |
52w Low $8.61 |
P/E 76.34 |
EPS 1.09 |
NEU released this announcement to the ASX on 8 August 2022, 9:14. The announcement is marked as price sensitive, and is 3 page(s) in length and 178.95kb in size.
You can view all announcements from NEU and see how they appear on a price chart on the announcements page.
At the date of this announcement, NEU was 0.001% short sold according to ASIC data. It was ranked the 668th most shorted stock on the ASX. It is now ranked as the 39th most shorted stock on the ASX with 5.756% of total shares short sold as of the latest reported data (05 May 2025).
| Other Recent Announcements from NEU | |
|---|---|
| Neuren completes enrolment in Phelan-McDermid Phase 2 trial | 30 June 2023, 9:36 |
| Neuren opens first site in US for Prader-Willi Phase 2 trial | 28 June 2023, 9:55 |
| Change of Director's Interest Notice | 14 June 2023, 18:44 |
| Neuren commences Phase 2 trials of NNZ-2591 in PMS and PTHS | 8 August 2022, 9:14 |
| Quarterly Activities/Appendix 4C Cash Flow Report | 29 July 2022, 9:47 |
| Acadia submits Rett Syndrome New Drug Application to the FDA | 19 July 2022, 9:46 |
| Neuren commences Phase 2 trial of NNZ-2591 in Angelman | 12 July 2022, 9:35 |
You must be logged in to post a reply.
Neuren Pharmaceuticals 